The Norwegian Government launches a National strategy for using Artificial Intelligence (AI)
On monday February 4th the Institute for Cancer Genetics and Informatics welcomed the Norwegian prime minister Erna Solberg, minister of digitalization Nikolai Astrup, Director of the South-Eastern Norway Regional Health Authority, Cathrine Lofthus and Director of the Cancer clinic at Oslo University Hosptial, Sigbjørn Smeland. Our Institute Director Håvard E. Greger Danielsen, the section for Interphase Genetics and the Section for Applied Informatics were able to demonstrate how artificial intelligence can contribute to cancer diagnosis, highlighting our research project www.domore.no.
Click here to read The Norwegian business daily Dagens Næringsliv's story about the Norwegian government's plans for a national AI strategy.
Can less cancer treatment be better treatment?
The Oslo University Hospital research blog "Ekspertsykehuset" challenged Tarjei Sveinsgjerd Hveem and communicator Kari Andresen from ICGI on how less cancer treatment may be the treatment of the future.
The DoMore! project, led by the ICGI, uses artificial intelligence to develop prognostic tools to diagnose cancer patients.
The blog is available in Norwegian only, click here to read the article.
The Institute on Instagram
ICGI works with images in many ways. Visualizations and image analysis are parts of our research and web design, photography, graphics and animated videos - all elements in our dissemination.
Follow us as @Icgidomore on Instagram to see our works. Our goal is to show a wide range of scientific and informational images and illustrations, some of them even slightly artistic.
Essential Facts on Ovarian Cancer
Kreftlex' video on ovarian cancer is now available in english on our Youtube channel. Kreftlex is our online cancer encyclopedia serving the Norwegian speaking population. The editorial board is part of our unit for dissemination and visualisation at the ICGI, and together with ovarian cancer specialists at Oslo University Hospital they have made this informative video on how ovarian cancer may occur and metastasise.
Please click here to go to www.kreftlex.no.
Kreftlex - the free cancer resource
Kreftlex editorial board at the ICGI is thrilled with the news that the NGO @Legatene now ensures continued operation and development by taking financial responsibility for www.kreftlex.no.
Read more about the Kreftlex project here
More accurate diagnostics for prostate cancer patients
Anyone who has been waiting on the results of a cancer test knows how horrible that time can be." Professor Håvard E. Danielsen has authored a blog-post on what artificial intelligence (AI) can do for prostate cancer patients (In Norwegian).
Click here to go to the Oslo University Hospital blog: "The expert Hospital"
What can digital image analysis do for cancer patients?
The atmosphere was informal when Professor Fritz Albregtsen of UiO and Institute for Cancer Genetics and Informatics - ICGI was interviewed by Teknisk Ukeblad`s journalist profile Odd Richard Valmot and chief editor Jan M Moberg about the possibility of using technological methods for prognosticating prostate cancer and other cancers.
Professor Albrigtsen is connected to our DoMore! project.
To read the article in Teknisk Ukeblad, and listen to the podcast, please click here.
A Lancet Oncology Podcast
The Lancet Oncology is a monthly journal, renowned for the publication of high-quality peer reviewed research, reviews and analysis in cancer from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue. In February 2018, Håvard Emil Danielsen joined The Lancet Oncology to discuss his latest paper on machine learning algorithms to analyse chromatin organisation as a prognostic marker for cancer.
Listen to Professor Håvard E. Danielsen from ICGI explain how machine learning and deep learning can supplement today's diagnostic methods for cancer. The conversation is based on the recently published article Chromatin Organization and Cancer Prognosis: a pan-cancer study.
A link to the podcast may be found here.
Ten years of CCB - a story of success
This final report summarizes ten years of excellent research at CCB – Centre for Cancer Biomedicine - a Norwegian Center of Excellence (CoE) at the Faculty of Medicine 2007–2017. Three of the highlighted achievements are:
- Identified characteristics of cancers that enable us to diagnose cancer at an early stage and tailor therapy to the individual patient.
- Uncovered fundamental molecular mechanisms of cancer suppression and development that provide new opportunities for diagnosis and therapy.
- With the world-leading interdisciplinary journals Nature and Science as a benchmark, CCB is among the most successful Norwegian CoEs with 13 papers in these journals. CCB scientists are senior authors of 8 of them.
Click here to read the full report from the Centre for Cancer Biomedicine
The same test, regardless of cancer type
Researchers at the Institute for Cancer Genetics and Informatics at Oslo University Hospital (OUS), have developed a method that can assess the seriousness of a patient's cancer and what treatment is required. A test can help understand the development of almost all types of cancer, and the results are now published in The Lancet Oncology: Chromatin organization and cancer prognosis: a pan-cancer study.
Today, there is no common test to diagnose and predict cancer. Instead, a variety of tests and methods are used for different types of cancer. Very few of them can provide a certain answer as to how cancer will develop. The consequence is that it is difficult to distinguish patients who need more treatment after surgery from those who do not need ANY. A significant number of patients today receive too much treatment, which may cause unnecessary side effects, damage and at worst, death.
The fresh research results are based on more than 20 years of collaboration between the Department of Cancer Genetics and Informatics at OUS and the Department of Informatics at The University of Oslo.
Initially, the method will be particularly useful for finding patients with Stage II intestinal cancer who will need more treatment after surgery, usually chemotherapy. Experiments show that the method can also be used for ovarian cancer, uterine cancer and prostate cancer.
Click here to read more about the Nucleotyping method.
As a supplement to the article on the Lancet Oncology website, a 3d animation was made by our unit for Dissertation and Visualization: